Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001388:Aziridines / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000628:therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007167:Immunotherapy; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000628:therapy; D007978:Levamisole / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008545:Melanoma / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013947:Thymosin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001500:BCG Vaccine; D007978:Levamisole; C016866:azimexon; D013947:Thymosin; D003520:Cyclophosphamide; D007930:Leucine; C012211:ubenimex; D008727:Methotrexate